Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Ann Ital Med Int ; 13(2): 121-4, 1998.
Artículo en Italiano | MEDLINE | ID: mdl-9734145

RESUMEN

We describe an unusual case of achalasia. The patient, a 33-year-old woman, presented with a clinical history of esophageal disease verified by gastroscopy. The diagnosis of hysterical anorexia that had been made some years previously did not correspond with the nosological classifications (DSM III-R, DSM IV). This case underscores the importance of the correct use of clinical methodology, particularly when conclusive diagnosis is essential for successful treatment.


Asunto(s)
Acalasia del Esófago/complicaciones , Hemorragia Gastrointestinal/etiología , Adulto , Anorexia/diagnóstico , Anorexia/terapia , Cateterismo , Diagnóstico Diferencial , Acalasia del Esófago/diagnóstico , Acalasia del Esófago/diagnóstico por imagen , Acalasia del Esófago/terapia , Femenino , Humanos , Radiografía
3.
J Int Med Res ; 18(5): 379-88, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2257960

RESUMEN

The efficacy and tolerability of Serratia peptidase were evaluated in a multicentre, double-blind, placebo-controlled study of 193 subjects suffering from acute or chronic ear, nose or throat disorders. Treatment lasted 7-8 days, with the drug or placebo being administered at a rate of two tablets three times a day. After 3-4 days' treatment, significant symptom regression was observed in peptidase-treated patients. There was also a significant reduction in symptoms after 7-8 days for patients in both treatment groups but the response was more marked in those patients receiving the active drug. Statistical comparison between the two groups confirmed the greater efficacy and rapid action of the peptidase against all the symptoms examined at both stages. Tolerance was found to be very good and similar for both groups. It is concluded that Serratia peptidase has anti-inflammatory, anti-oedemic and fibrinolytic activity and acts rapidly on localized inflammation.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Enfermedades Otorrinolaringológicas/tratamiento farmacológico , Péptido Hidrolasas/uso terapéutico , Enfermedad Aguda , Adolescente , Anciano , Enfermedad Crónica , Método Doble Ciego , Femenino , Humanos , Laringitis/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Dolor/tratamiento farmacológico , Faringitis/tratamiento farmacológico , Sinusitis/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA